Clinical trialNCT06679101RecruitingPhase 3Interventional

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

SponsorGlaxoSmithKlineEnrollment520Multiple MyelomaNewly Diagnosed Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

181 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Gsk Investigational Site
Capital Federal, Argentina
Paola Ochoa
Recruiting
Gsk Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
Vanesa Caruso
Recruiting
Gsk Investigational Site
Córdoba, Argentina
Jorge Salinas
Recruiting
Gsk Investigational Site
Rosario, Argentina
Herman Perroud
Recruiting
Gsk Investigational Site
Viedma, Argentina
Rubén Kowalyszyn
Recruiting

Australia

Gsk Investigational Site
Gosford NSW, New South Wales, Australia
Catherine Tang
Recruiting
Gsk Investigational Site
Box Hill, Victoria, Australia
Olga Motorna
Recruiting
Gsk Investigational Site
Melbourne, Victoria, Australia
Sueh-Li Lim
Recruiting
Gsk Investigational Site
Fitzroy, Australia
Hang Quach
Recruiting
Gsk Investigational Site
Herston, Australia
Nicholas Weber
Recruiting
Gsk Investigational Site
St Leonards, Australia
Chris Ward
Recruiting

Belgium

Gsk Investigational Site
Bruges, Belgium
Jan Van Droogenbroeck
Recruiting
Gsk Investigational Site
Brussels, Belgium
Marie-Christiane Vekemans
Recruiting
Gsk Investigational Site
Ghent, Belgium
Nicolas Kint
Recruiting
Gsk Investigational Site
Hornu, Belgium
Julien Depaus
Recruiting
Gsk Investigational Site
Roeselare, Belgium
Rutger Callens
Recruiting

Brazil

Gsk Investigational Site
Salvador, Estado de Bahia, Brazil
Edvan de Queiroz Crusoe
Recruiting
Gsk Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Laura Fogliatto
Recruiting
Gsk Investigational Site
Barretos, Brazil
Mariana Bianchi Carneiro
Recruiting
Gsk Investigational Site
Joinville, Brazil
Marcelo Pitombeira Lacerda
Recruiting
Gsk Investigational Site
Porto Alegre, Brazil
Marcelo Capra
Recruiting
Gsk Investigational Site
São Paulo, Brazil
Gracia Aparecida Martinez
Recruiting
Gsk Investigational Site
São Paulo, Brazil
Jayr Schmidt Filho
Recruiting
Gsk Investigational Site
São Paulo, Brazil
Abel Costa
Recruiting
Gsk Investigational Site
São Paulo, Brazil
Vania Hungria
Recruiting
Gsk Investigational Site
Teresina, Brazil
Claudio Lima Rocha
Recruiting
Gsk Investigational Site
Vitória, Brazil
Marcelo Alves Aduan
Recruiting

Canada

Gsk Investigational Site
Saint John, New Brunswick, Canada
Anthony Reiman
Recruiting

China

Gsk Investigational Site
Beijing, China
Hongmei Jing
Recruiting
Gsk Investigational Site
Chengdu, China
xiaobing huang
Recruiting
Gsk Investigational Site
Chongqing, China
Hongbin Zhang
Recruiting
Gsk Investigational Site
Guangzhou, China
Zhong-jun xia
Recruiting
Gsk Investigational Site
Guangzhou, China
Yongqiang Wei
Recruiting
Gsk Investigational Site
Hangzhou, China
Jie Jin
Recruiting
Gsk Investigational Site
Nanchang, China
qingming Wang
Recruiting
Gsk Investigational Site
Nanchang, China
Fei Li
Recruiting
Gsk Investigational Site
Nanjing, China
Bing Chen
Recruiting
Gsk Investigational Site
Shanghai, China
Peng Liu
Recruiting
Gsk Investigational Site
Shanghia, China
Weijun Fu
Recruiting
Gsk Investigational Site
Shenzhen, China
Yicheng Zhang
Recruiting

141 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Belantamab mafodotin →Daratumumab →Dexamethasone →Lenalidomide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Dec 2024
Primary completion: 28 Apr 2031
Completion: 28 Apr 2031
Last update posted: 22 Apr 2026
Registered enrollment: 520
Registry id: NCT06679101

Cross-registrations

EU-CTR / CTIS (EudraCT)2024-516030-35

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.